Allarity Therapeutics Receives Nasdaq-Approved Extension to Regain Compliance With Nasdaq Listing Rule 5550(B)(1)
Alarity Therapeutics获得纳斯达克批准的延期,以恢复对纳斯达克上市规则5550(B)(1)的遵守
Allarity Therapeutics Receives Nasdaq-Approved Extension to Regain Compliance With Nasdaq Listing Rule 5550(B)(1)
Alarity Therapeutics获得纳斯达克批准的延期,以恢复对纳斯达克上市规则5550(B)(1)的遵守
使用浏览器的分享功能,分享给你的好友吧